Liaoning Chengda Biotechnology Co.,Ltd.

688739

CNE100004ZP2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
27.29 ^CNY	+0.59%		-0.58%	-16.06%

May. 20	Wall Street Cues, Central Bank Outlooks Lift Asian Stock Markets	MT
Apr. 29	Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback Plan announced on September 18, 2023.

October 08, 2023 at 10:59 pm EDT

From September 15, 2023 to September 30, 2023, the company has repurchased 730,578 shares, representing 0.18% for CNY 25.2 million. With this, the company has completed the repurchase of 730,578 shares, representing 0.18% for CNY 25.2 million under the buyback announced on September 18, 2023.

Latest news about Liaoning Chengda Biotechnology Co.,Ltd.

Wall Street Cues, Central Bank Outlooks Lift Asian Stock Markets	May. 20	MT
Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Tech Sector Galvanizes Asian Stock Markets	Apr. 24	MT
Tranche Update on Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback Plan announced on March 12, 2024.	Apr. 01	CI
Hong Kong-listed Samsonite plans dual listing in hunt for investors	Mar. 21	RE
Central Bank Prospects Churn Asian Stock Markets	Mar. 20	MT
Hong Kong Shares Inch Up After China Holds Benchmark Rates Steady; Qyuns Therapeutics Falls 9% on Debut	Mar. 20	MT
Li Ning's 2023 Profit Falls as Selling, Admin Costs Rise	Mar. 19	MT
Global markets live: Domino's Pizza, Generali, Oracle, Intel, Boeing...	Mar. 12
China's champion gymnast Li Ning considers taking company private, sources say	Mar. 12	RE
China's champion gymnast Li Ning considers taking company private, sources say	Mar. 12	RE
CHINESE OLYMPIC CHAMPION LI NING CONSIDERS TAKING PRIV…	Mar. 12	RE
Liaoning Chengda Biotechnology Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	Mar. 11	CI
Liaoning Chengda Biotechnology Co.,Ltd. authorizes a Buyback Plan.	Mar. 10	CI
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Wall Street Cues Nudge Asian Stock Markets Higher	Feb. 15	MT
Hong Kong Stocks Rise on Strong Fed Rate Cut Bets; Li Ning Jumps 5%	Feb. 15	MT
Fed, China Property Outlooks Roil Asian Stock Markets	Feb. 01	MT
New entry in MarketScreener's Asia portfolio	Jan. 10
News Highlights : Top Company News of the Day	Dec. 24	DJ
Tranche Update on Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback Plan announced on September 18, 2023.	Dec. 20	CI
Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback announced on September 18, 2023, has closed with 2,251,804 shares, for CNY 74.8 million.	Dec. 20	CI
Global markets live: Nokia, Oracle, AstraZeneca, Nvidia, Hasbro...	Dec. 12
Li Ning to Buy HK Building for HK$2.2 Billion to House New HQ; Shares Up 4%	Dec. 11	MT

Chart Liaoning Chengda Biotechnology Co.,Ltd.

Duration

Period

Chart Liaoning Chengda Biotechnology Co.,Ltd.

More charts

Company Profile

Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.29 CNY

Average target price

32 CNY

Spread / Average Target

+17.26%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD.	-16.06%	1.56B
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
BIOGEN INC.	-13.07%	32.75B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B

Biopharmaceuticals

Liaoning Chengda Biotechnology Co.,Ltd.

Equities

688739

CNE100004ZP2

Pharmaceuticals

Tranche Update on Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback Plan announced on September 18, 2023.

Latest news about Liaoning Chengda Biotechnology Co.,Ltd.

Chart Liaoning Chengda Biotechnology Co.,Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

Annual profits - Rate of surprise

Sector Biopharmaceuticals